Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

Item
http://www.wikidata.org/entity/Q37094837
Systematic Analysis Reveals Elongation Factor 2 and α-Enolase as Novel Interaction Partners of AKT2Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)The critical role of Akt in cardiovascular functionUsing high-throughput sequencing transcriptome data for INDEL detection: challenges for cancer drug discovery.Akt inhibitors: mechanism of action and implications for anticancer therapeutics.Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivoNuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway.Human platelet lysate improves human cord blood derived ECFC survival and vasculogenesis in three dimensional (3D) collagen matricesA Switch in Akt Isoforms Is Required for Notch-Induced Snail1 Expression and Protection from Cell DeathAKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.Role of PRAS40 in Akt and mTOR signaling in health and disease.Use of PD biomarkers to drive dose selection and early clinical decision making.A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.PRAS40 signaling in tumor.In vitro and in vivo anti-tumor and anti-inflammatory capabilities of the novel GSK3 and CKD9 inhibitor ABC1183.
P2860

Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.

Item
http://www.wikidata.org/entity/Q37094837
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical pharmacology, anti ...... otent AKT inhibitor CCT128930.
@en
Preclinical pharmacology, anti ...... otent AKT inhibitor CCT128930.
@nl
type
label
Preclinical pharmacology, anti ...... otent AKT inhibitor CCT128930.
@en
Preclinical pharmacology, anti ...... otent AKT inhibitor CCT128930.
@nl
prefLabel
Preclinical pharmacology, anti ...... otent AKT inhibitor CCT128930.
@en
Preclinical pharmacology, anti ...... otent AKT inhibitor CCT128930.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P932
P356
P1433
P1476
Preclinical pharmacology, anti ...... otent AKT inhibitor CCT128930.
@en
P2093
P2860
P304
P31
P356
10.1158/1535-7163.MCT-10-0760
P433
P478
P50
P577
P698
P921
P932